CDKN2A and lung carcinoma: In another genomic study of BM of various origin, several potentially actionable genomic alterations were associated with lung cancer BM, including AKT1, AURKA, CDK6, EGFR, MEK1, MET, and PIK3CA gene amplifications and CDKN2A deletions.8